A detailed history of Park National Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Park National Corp holds 146,099 shares of ABBV stock, worth $28.5 Million. This represents 0.94% of its overall portfolio holdings.

Number of Shares
146,099
Previous 134,426 8.68%
Holding current value
$28.5 Million
Previous $24.5 Million 2.37%
% of portfolio
0.94%
Previous 0.95%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 15, 2024

BUY
$154.79 - $180.76 $1.81 Million - $2.11 Million
11,673 Added 8.68%
146,099 $25.1 Million
Q1 2024

Apr 01, 2024

SELL
$159.82 - $182.1 $1.72 Million - $1.96 Million
-10,771 Reduced 7.42%
134,426 $24.5 Million
Q4 2023

Jan 02, 2024

SELL
$137.6 - $154.97 $916,828 - $1.03 Million
-6,663 Reduced 4.39%
145,197 $22.5 Million
Q3 2023

Oct 02, 2023

BUY
$133.59 - $154.65 $440,179 - $509,571
3,295 Added 2.22%
151,860 $22.6 Million
Q2 2023

Jul 03, 2023

BUY
$132.51 - $164.9 $1.05 Million - $1.3 Million
7,907 Added 5.62%
148,565 $20 Million
Q1 2023

Apr 03, 2023

BUY
$144.61 - $166.54 $5.76 Million - $6.63 Million
39,840 Added 39.52%
140,658 $22.4 Million
Q4 2022

Feb 06, 2023

SELL
$138.31 - $165.87 $1.23 Million - $1.48 Million
-8,921 Reduced 8.13%
100,818 $16.3 Million
Q3 2022

Oct 03, 2022

BUY
$134.21 - $153.93 $4.52 Million - $5.18 Million
33,673 Added 44.27%
109,739 $14.7 Million
Q2 2022

Jul 01, 2022

SELL
$137.62 - $174.96 $325,884 - $414,305
-2,368 Reduced 3.02%
76,066 $11.7 Million
Q1 2022

Apr 01, 2022

SELL
$131.98 - $163.75 $904,194 - $1.12 Million
-6,851 Reduced 8.03%
78,434 $12.7 Million
Q4 2021

Jan 04, 2022

SELL
$107.43 - $135.93 $1.79 Million - $2.27 Million
-16,698 Reduced 16.37%
85,285 $11.5 Million
Q3 2021

Oct 01, 2021

SELL
$106.4 - $120.78 $614,460 - $697,504
-5,775 Reduced 5.36%
101,983 $11 Million
Q2 2021

Jul 01, 2021

SELL
$105.21 - $117.21 $1.18 Million - $1.32 Million
-11,248 Reduced 9.45%
107,758 $12.1 Million
Q1 2021

Apr 01, 2021

SELL
$102.3 - $112.62 $3.17 Million - $3.49 Million
-30,965 Reduced 20.65%
119,006 $12.9 Million
Q4 2020

Jan 04, 2021

SELL
$80.49 - $108.67 $944,952 - $1.28 Million
-11,740 Reduced 7.26%
149,971 $16.1 Million
Q3 2020

Oct 01, 2020

SELL
$85.91 - $100.83 $2.81 Million - $3.3 Million
-32,680 Reduced 16.81%
161,711 $14.2 Million
Q2 2020

Jul 01, 2020

SELL
$73.37 - $98.18 $844,635 - $1.13 Million
-11,512 Reduced 5.59%
194,391 $19.1 Million
Q1 2020

Apr 01, 2020

SELL
$64.5 - $97.79 $1.14 Million - $1.74 Million
-17,746 Reduced 7.93%
205,903 $15.7 Million
Q4 2019

Jan 02, 2020

SELL
$72.13 - $90.25 $976,712 - $1.22 Million
-13,541 Reduced 5.71%
223,649 $19.8 Million
Q3 2019

Oct 01, 2019

SELL
$62.98 - $75.72 $4.31 Million - $5.19 Million
-68,495 Reduced 22.41%
237,190 $18 Million
Q2 2019

Jul 01, 2019

BUY
$65.7 - $83.98 $359,510 - $459,538
5,472 Added 1.82%
305,685 $22.2 Million
Q1 2019

Apr 01, 2019

BUY
$77.14 - $90.79 $1.15 Million - $1.35 Million
14,906 Added 5.22%
300,213 $24.2 Million
Q4 2018

Jan 02, 2019

BUY
$77.85 - $96.01 $1.21 Million - $1.49 Million
15,569 Added 5.77%
285,307 $26.3 Million
Q3 2018

Oct 02, 2018

BUY
$88.91 - $98.84 $466,332 - $518,415
5,245 Added 1.98%
269,738 $25.5 Million
Q2 2018

Jul 02, 2018

BUY
$89.78 - $106.23 $591,021 - $699,312
6,583 Added 2.55%
264,493 $24.5 Million
Q1 2018

Apr 02, 2018

SELL
$92.01 - $123.21 $1.7 Million - $2.27 Million
-18,426 Reduced 6.67%
257,910 $24.4 Million
Q4 2017

Jan 02, 2018

SELL
$89.56 - $98.21 $1.29 Million - $1.42 Million
-14,447 Reduced 4.97%
276,336 $26.7 Million
Q3 2017

Oct 02, 2017

BUY
$69.85 - $89.22 $20.3 Million - $25.9 Million
290,783
290,783 $25.8 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Park National Corp Portfolio

Follow Park National Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park National Corp , based on Form 13F filings with the SEC.

News

Stay updated on Park National Corp with notifications on news.